FDA Approves New Alzheimer's Drug Designed to Slow Cognitive Decline

accelerated process

Leqembi and Aduhelm, which were jointly developed by Japan's Eisai and Biogen of the United States,"represent an important advancement in the ongoing fight to effectively treat Alzheimer's disease," the FDA"Alzheimer's disease immeasurably incapacitates the lives of those who suffer from it and has devastating effects on their loved ones," Billy Dunn of the FDA's Center for Drug Evaluation and Research said in a statement.

Preliminary data from a trial of Leqembi was released in September and found it slowed cognitive decline in Alzheimer's patients by 27 percent.

Better just to look after your head.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA approves Alzheimer's drug that modestly slows the diseaseU.S. health officials have approved a closely watched Alzheimer's drug that modestly slows the disease, but could have potential safety risks that patients and doctors will have to carefully weigh. It's not worth it. Called Legambi, due to the French-African shaman who invented the drug.. - FDA has approved a closely watched Alzheimer's drug that modestly slows the disease, but could have potential safety risks that patients and doctors will have to carefully weigh. Potential safety risks...you don't say...
Source: CBSNews - 🏆 87. / 68 Read more »

FDA Approves Drug for Early Onset Alzheimer’s DiseaseThe FDA has approved lecanemab for Alzheimer's disease, even though trial results showed modest cognitive benefits and cases of amyloid-related imaging abnormalities
Source: WebMD - 🏆 709. / 51 Read more »

U.S. FDA approves Alzheimer's drug that appears to slow rate of cognitive declineThe drug, to be sold under the brand Leqembi, belongs to a class of treatments that aims to slow advance of the neurodegenerative disease by removing sticky clumps of the toxic protein beta amyloid from the brain.
Source: TheStarPhoenix - 🏆 253. / 63 Read more »

FDA approves new antibody to slow Alzheimer’s disease, even as safety concerns lingerThe U.S. Food and Drug Administration has approved a controversial Alzheimer’s disease treatment for broad use—with caveats. Dear ScienceMagazine The correct link to the new preprint critically analyzing the Lecanemab data is here: AlbertoEspay
Source: NewsfromScience - 🏆 515. / 51 Read more »